2026-06-03T22:30:01Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/339342026-02-03T10:58:23Zcom_10630_2254col_10630_37953

García-León, Juan Antonio López-Gómez, Carlos Orpez-Zafra, Teresa Reyes-Garrido, Virginia Marín Bañasco, Carmen Oliver-Martos, Begoña Fernández-Fernández, Óscar Leyva-Fernández, Laura 2024-09-29T18:31:53Z 2024-09-29T18:31:53Z 2014 García-León JA, López-Gómez C, Orpez-Zafra T, Reyes-Garrido V, Marín-Bañasco C, Oliver-Martos B, Fernández O, Leyva L. Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical response. CNS Drugs. 2014 Jun;28(6):559-70. doi: 10.1007/s40263-014-0153-7. PMID: 24599774. https://hdl.handle.net/10630/33934 10.1007/s40263-014-0153-7 Background: Both the adaptative and the innate immune systems interplay in multiple sclerosis (MS) pathogeny. Killer-cell immunoglobulin-like receptors (KIRs) are key regulators of the immune response, with activating and inhibitory isoforms. Objective: In this study we analysed whether the expression of KIR isoforms is implicated in MS pathogenesis and in the therapeutic response to interferon (IFN)-β. Methods: Peripheral blood samples were collected from 78 IFN-β-treated MS patients and 46 healthy controls (HC). KIR expression was evaluated by flow cytometry on natural killer (NK) and T cells. Results: The expression of KIRs on NK cells and T lymphocytes did not differ between MS patients and HC. IFN-β therapy decreased the expression of KIR2DL1/2DS1 and increased that of KIR2DL2/3 on NK cells. This therapy also reduced KIR2DL1/2DS1, KIR2DL2/2DL3 and KIR3DL2 expression on CD8(+) T cells. The baseline evaluation of the percentage of circulating CD16(+) NK cells was predictive of the clinical response to IFN-β; however, response to this therapy did not appear related to KIR expression. Conclusions: This study shows that expression of KIR isoforms on NK and T lymphocytes correlated in different ways with IFN-β therapy, suggesting that KIR dynamics may be associated with the pathways involved in the mechanisms of action of IFN-β. eng open access Esclerosis múltiple Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical response journal article